3002.15.20 — Basiliximab (DCI); bevacizumab (DCI); daclizumab (DCI); etanercept (DCI); gemtuzumab ozogamicin (DCI); oprelvekin (DCI); rituximab (DCI); trastuzumab (DCI)

NCM Code Details

NCM Code

3002.15.20

HS6 Cross-Reference

300215

Descrição

Basiliximab (DCI); bevacizumab (DCI); daclizumab (DCI); etanercept (DCI); gemtuzumab ozogamicin (DCI); oprelvekin (DCI); rituximab (DCI); trastuzumab (DCI)

Vigência: 01/04/2022 – 31/12/9999

HS6 Cross-Reference

The first 6 digits of any NCM code (300215) correspond to the international Harmonized System (HS) subheading — identical across all WCO member countries. This enables direct comparison with US HTS, UK Commodity Codes, EU CN/TARIC, and Canadian tariff items.